New UK-based biotech Nucleome Therapeutics has gained backing from several big pharma venture funds to help fund its mission to decode the “dark matter” of the human genome and discover first-in-class precision medicines.
New ‘Dark Genome’ Biotech Gets Backing From Big Pharma Venture Funds
Autoimmune Diseases Will Be First Target
The Oxford University spin-out has raised $37.5m in a series A thanks to its technology which pinpoints the link between genes and diseases and maps pathways for drug discovery.
